Accueil>>Signaling Pathways>> Angiogenesis>> BTK>>Tirabrutinib hydrochloride (ONO-4059 (hydrochloride))

Tirabrutinib hydrochloride (ONO-4059 (hydrochloride)) (Synonyms: GS-4059, ONO-WG-307)

Catalog No.GC34097

Le chlorhydrate de tirabrutinib (ONO-4059) est un inhibiteur de la tyrosine kinase (BTK) de Bruton's actif par voie orale (peut traverser la barrière hémato-encéphalique (BHE)), avec une CI50 de 6,8 nM.

Products are for research use only. Not for human use. We do not sell to patients.

Tirabrutinib hydrochloride (ONO-4059 (hydrochloride)) Chemical Structure

Cas No.: 1439901-97-9

Taille Prix Stock Qté
5mg
56,00 $US
En stock
10mg
93,00 $US
En stock
25mg
185,00 $US
En stock
50mg
324,00 $US
En stock
100mg
556,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tirabrutinib (ONO-4059) hydrochloride is a selective and novel inhibitor of BTK with IC50 2.2 nm, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.

[1]. Akintunde Akinleye et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol, 2013, 6: 59. [2]. Harriet S et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 2016, 127:411-419.

Avis

Review for Tirabrutinib hydrochloride (ONO-4059 (hydrochloride))

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tirabrutinib hydrochloride (ONO-4059 (hydrochloride))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.